Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion type Assertion NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_head.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion description "[Chimeric antigen receptor (CAR)-modified T cells targeting CD19 expressed by normal and malignant B cells is a unique therapy for patients with chronic lymphocytic leukemia (CLL); recent results highlight the potential of this therapy for patients with relapsed CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion evidence source_evidence_literature NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion SIO_000772 23561477 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion wasDerivedFrom befree-20140225 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.
- NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_assertion wasGeneratedBy ECO_0000203 NP833699.RArCrQL3kVviuQLmI3Ef8dR9ZtYZDmr3fPneXVz_jZvvg130_provenance.